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Introductory Chapter: Gene 




Gene editing is a type of genetic engineering in which DNA is inserted, deleted, 
modified, or replaced in the genome of a living organism. Unlike traditional meth-
ods that randomly insert genetic material into a host genome, current gene editing 
technologies target and change the specific genome locations. Zinc finger nucleases 
(ZFNs), transcription activator-like effectors nucleases (TALENs), and clustered 
regularly interspaced short palindromic repeats (CRISPRs)/Cas9 nuclease system 
are the three common gene editing technologies. These technologies have been 
widely used in genome engineering to enable a broad range of mutation by inducing 
DNA breaks that stimulate error-prone repairs such as homologous recombination 
(HR) or nonhomologous end joining (NHEJ). They successfully make it possible to 
achieve site-specific editing, modification, and manipulation at specific genomic 
sites (Table 1) [1].
1.1 ZFNs
ZFNs are artificial restriction enzymes generated by fusing a zinc finger-specific 
DNA-binding domain to a nonspecific DNA cleavage domain. The specific binding 
domains of individual ZFNs typically contain between three and six individual 
zinc finger repeats and can each recognize between 12 and 18 base pairs. If the zinc 
finger domains are specific for their intended target site, then even a pair of three-
finger ZFNs that recognize a total of 18 base pairs can target a single locus in a mam-
malian genome. The nonspecific cleavage domain from the restriction endonuclease 
Fok I is typically used as the cleavage domain in ZFNs. This cleavage domain must 
form a dimer in order to cleave DNA, and thus a pair of ZFNs are required to target 
nonpalindromic DNA sites [2] (Figure 1).
1.2 TALENs
Transcription activator-like effectors (TALEs) are proteins secreted by bacteria 
Xanthomonas via type III secretion system when they infect various plant species. 
TALEs are important virulence factors that act as transcriptional activators in the 
plant cell nucleus [3]. Each TALE contains a central repetitive region consisting of 
varying numbers of repeat units (about 17.5 repeats) of 34 amino acids [3, 4]. The 
DNA-binding domain contains a highly conserved 34 amino acid sequence with 
the exception of the 12th and 13th amino acids [3]. Only the 12th and 13th amino 
acids in TALEs are changeable and variable, the other amino acids are constant and 
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stable. These two locations—repeat variable di-residues (RVD) are highly variable 
and show a strong correlation with a specific nucleotide recognition by differ-
ent frequency, for example, NI recognize A (55%), NG recognize T (50%), NN 
recognize G (7%), and HD recognize C(69%) [3]. Two amino acids have known to 
recognize one nucleotide after the breaking of code of DNA-binding specificity of 
Figure 1. 
ZFNs are chimeric nucleases consisting of specific DNA-binding modules linked to a nonspecific cleavage 
domain. Right and left ZFNs containing Fok I endonucleases link to an array of 3–6 zinc fingers that have 
been designed to specifically recognize target sequences (12 green and 12 purple boxes), respectively. The ZFN 
targets are separated by typically 5 or 6 bp. Two Fok I work as a homodimer to cleave the sense strand 1 bp and 
antisense strand 5 bp downstream of the binding site.
Technology ZFN TALEN CRISPR/Cas9








Zinc finger protein TALE SgRNA
Nuclease Fok I Fok I Cas9
Restriction for a target 
sequence
Rich in cytosine No special restriction PAM
Target site Two (left and right) Two (left and right) Only one
Length of target gene 12–18 bp 12–18 bp 18–23 bp
Mode of action Two proteins act on 
two target sites
Two proteins act on two 
target sites
RNA and Cas9 act on 
one target site
Cleavage site DSB with a sticky 
end
DSB with a sticky end DSB with a blunt end
Efficiency Medium Medium High
Ease of engineering Low Medium High
Ease of characterization Low Medium High
Cost High Medium Low
Cytotoxicity High Low Low
Off target Yes Yes Yes
Abbreviations: CRISPR, clustered regularly interspaced short palindromic repeat; DSB, double-strand break; Fok, 
Flavobacterium okeanokoites; PAM, protospacer adjacent motif; TALE, transcription activator-like effector; sgRNA, 
single guide RNA; and ZFN, zinc finger nuclease.
Table 1. 
Comparison of different gene editing technologies.
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TALEs [3, 4]. The restriction endonuclease Fok I consists of an N-terminal specific 
DNA-binding domain and a C-terminal nonspecific DNA cleavage domain. The 
nonspecific DNA cleavage domain of Fok I cleaves the double-strand DNA (DSB) 
at a fixed distance of 9 and 13 nucleotides downstream of the recognition site [5]. 
TALENs are artificial restriction enzymes generated by fusing the specific TALE 
DNA-binding domain to a nonspecific Fok I DNA cleavage domain [6–8] (Figure 2).
1.3 CRISPRs/Cas9
The CRISPRs/Cas9 system, originally found in the bacteria, functions as an 
adaptive immune system against foreign virus or plasmid DNA. CRISPRs are 
DNA loci containing short repetitions of base sequences. Each repetition is fol-
lowed by short segments of spacer DNA from previous exposures to the foreign 
DNA. CRISPR-associated protein (Cas9) is a DNA endonuclease whose structure is 
bilobed, composed of target recognition domain and nuclease lobes. The nuclease 
Figure 2. 
The specific repeat variable Di-residues (RVDs) used to recognize each base are defined in the key (NI:A, 
NG:T, NN:G, and HD:C). Left and right TALEs recognize their target sequences and allow their associated Fok 
I endonucleases to work as a homodimer to cleave the sense strand 9 bp and antisense strand 13 bp downstream 
of the binding site. Binding of TALEs to the target sites allows Fok I to dimerize and create a double-strand 
break (DSB) with sticky ends within the spacer.
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lobe contains nucleases RuvC, HNH, and a carboxyl-terminal domain for the 
protospacer adjacent motif (PAM) recognition [9]. The Type II CRISPRs system is 
currently limited to target sequences that are N12-20NGG, where NGG represents 
the PAM sequence [10]. Any potential target sequence must have a specific PAM 
sequence on its 3′ end. The CRISPR locus consists of Cas9 endonucleases, CRISPRs 
RNAs (crRNAs), trans-activating crRNAs (tracrRNAs), and precursor crRNAs 
(pre-crRNAs). tracrRNA is partially complementary to and pairs with a pre-crRNA 
to form an RNA duplex cleaved by RNase III. The crRNA/tracrRNA hybrid acts as 
a single guide RNA (sgRNA) for the Cas9, which cleaves the invading DNA. The 
DNA target sites can appear in multiple locations, all of which will be targeted by 
the Cas9 for cleavage. By delivering the Cas9 protein and appropriate sgRNAs into a 
cell, the organism’s genome can be cut at most locations with the only limitation of 
PAM availability (Figure 3).
2. Application
2.1 Tools for basic research
2.1.1 Genetic cloning of living organisms
For conventional genetic cloning of animals, plants, and microbes, the target 
genes in the specific genome are cut using restriction enzymes. It usually takes lots 
of work and long time to clone and screen for the desired ones. Current gene editing 
technologies can be used to achieve the desired clones both quickly and accurately, 
without the limitation of restriction site availability [11].
2.1.2 Establishment of animal models
Genetic cloning, gene knock-in, and gene knockout are the most common 
methods to make induced or experimental animal models. The efficient approaches 
Figure 3. 
A crRNA/tracrRNA hybrid acts as a single guide RNA (sgRNA) to recognize their target sequences and allow 
Cas9 endonucleases to cleave the sense strand 3 bp and antisense strand 3 bp upstream of the protospacer 
adjacent motif (PAM) sequence. Binding of sgRNAs to the target sites makes Cas9 create a double-strand break 
(DSB) with blunt ends on target sequences.
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include ZFNs, TALENs, and CRISPRs/Cas9. By these new gene editing technologies, 
specific animal models of many diseases for which there are no animal models avail-
able previously have been established with unprecedented efficiency and precision 
[12–14].
2.1.3 Development of testing tools and reagents
CRISPRs/Cas9 can be optimized by bacterial genotypes to be more adaptive 
to the variation of food pathogens, compared with traditional methods. The 
CRISPR locus of different bacterial species show high variance to be an ideal basis 
for genotyping [15]. The CRISPR/Cas12a(Cpf1) DETECTR (DNA endonuclease 
targeted CRISPR trans reporter) system can be used to diagnose gene mutations, 
cancers, and microbial infections and test microbial antibiotic resistance by analyz-
ing specimens [16].
2.1.4 Discovery of drugs
The screening and identification of target sites are critical to drug discovery; 
thus, excellent and suitable platforms are needed. Gene editing technologies 
can work for the editing of functional genes and the screening of target sites. 
For example, CRISPRs/Cas9 was used to target the exons encoding functional 
protein domains. A screen of 192 chromatin regulatory domains in murine acute 




The gene editing technology can be used to produce agricultural products in 
accordance with the need of humans. For example, crops were produced with high 
yield and resistant to diseases, insects, herbicides, and harsh environment [18, 19]; 
domesticated animals (pig, buffalo) were produced with double muscle phenotype 
[20]; and aquatic products (catfish) were produced with high level myostatin 
(MSTN) gene expression [21].
2.2.2 Food
We can make food more productive or have longer shelf-life by gene editing 
technologies. For example, CRISPRs/Cas9 was used to edit thermophilic bacteria 
Streptococcus thermophilus as a bacteriophage-insensitive mutant to improve the 
product (e.g., yogurt, cheese) yield by refraining from the infection of phages [22]. 
The white button mushroom Agaricus bisporus was engineered to resist browning 
using CRISPRs/Cas9. The effect was achieved by targeting to knock out the genes 
that encodes polyphenol oxidase—an enzyme that causes browning [23].
2.2.3 Industrial products
CRISPRs/Cas9 has been used to establish marine algae (e.g., diatoms) as useful 
in industrial applications as the carbon neutral synthesis of fuels, pharmaceuticals, 
health foods, biomolecules, materials related to nanotechnology, and bioreme-
diations of contaminated water [24, 25]. CRISPRs/Cas9 was used to encode the 
pixel values of black and white images and a short movie into the living bacterial 
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genomes. By CRISPRs/Cas9, the technical limits of this information storage system 
can be optimized to be minimal. CRISPRs/Cas9 can capture and stably store many 
real data within the genomes of living cells [26].
2.2.4 Environmental protection
Marine microalgae are in charge of about 40% of primary production on earth 
and capture more CO2 than rain forests. Diatoms are the most important unicellular 
eukaryotic microalgae and have dominant ecological significance. CRISPRs/Cas9 
can be used to modify the diatom genome to achieve more effects in reducing the 
global warming [25].
2.2.5 Restoration of extinct animals
Woolly mammoths are different from current living elephants by adapting 
to the extreme cold environment. The mammoth TRPV3 gene, which encodes a 
temperature-sensitive transient receptor potential (thermoTRP) channel involved 
in thermal sensation and hair growth, could be achieved by modifying genes 
of Asian elephants [27]. The mammoth may be restored using CRISPRs/Cas9, 




The therapeutic strategies of Parkinson’s disease (PD) are quite variable includ-
ing drug and nondrug treatment. Therefore, it is necessary to find a suitable 
strategy to treat PD safely, efficiently, and quickly. A novel tool was established for 
monitoring endogenous alpha-synuclein (α-SYN) transcription by NanoLuc lucif-
erase tag insertion at the 3′ end using CRISPRs/Cas9, and thus making it possible to 
screen for strategies rapidly that can be used for PD therapy efficiently [28].
2.3.2 Preparation for cell therapy or immunotherapy
The gene-editing technology can be applied to engineer induced pluripotent 
stem (iPS) cells and chimeric antigen receptor T (CART) cells. CRISPRs/Cas9 has 
been used to engineer iPS cells to evade immune rejection in full immunocompetent 
allogeneic recipients [29]. Because the CD19 CAR was successfully used in treat-
ment, CRISPRs/Cas9 may further enhance the efficacy and safety of CART cells by 
engineering therapeutic T cells [30].
2.3.3 Potential application for disease treatment
2.3.3.1 Virus latent infection
Diseases caused by viruses are difficult to treat due to their high mutation rates 
and latent infections. It is almost impossible to eradicate latent viruses in the human 
host. However, TALENs and CRISPRs/Cas9 have been found to provide good strate-
gies in targeting viruses and limiting their productive and latent infections ex vivo 
and/or in vivo, such as herpes simplex virus 1 (HSV-1), Epstein-Barr virus (EBV), 
human cytomegalovirus (HCMV), human immunodeficiency virus (HIV), and 
hepatitis B virus (HBV) [31–36].
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2.3.3.2 Genetic disease
Genetic diseases can be cured by gene therapies such as sickle cell anemia, 
β-thalassemia, muscular dystrophy, α1-antitrypsin deficiency, Leber congenital 
amaurosis, and cystic fibrosis [37]. The gene editing technologies (e.g., CRISPRs/
Cas9) potentially facilitate the progress of gene therapy, because many experiments 
have been successful ex vivo and in vivo, and some of them are being under clinical 
trials.
2.3.3.3 Neurodegenerative disease
By applying the Perturbing Regulatory Interactions by Synthetic Modulators 
(PRISM) to a yeast model of PD, sgRNAs were identified to modulate transcrip-
tional networks and protect cells from α-Syn toxicity [38]. The APPswe (Swedish) 
mutation in the amyloid precursor protein (APP) gene causes Alzheimer’s disease 
(AD). The mutant APPSW allele can be selectively disrupted using CRISPRs/Cas9 
both ex vivo and in vivo and thereby decrease pathogenic amyloid-β (Aβ) [39].
2.3.3.4 Cancer
CRISPRs/Cas9 were tried to inhibit hepatocellular carcinoma (HCC). miR-125b 
can suppress the expression of SIRT6 by directly targeting the seed-matching region 
of its 3′UTR. After the expression of SIRT6 knocked out through CRISPRs/Cas9, 
HCC cells showed the decreased viability and invasiveness, which had the similar 
function upon the overexpression of the miR-125b [40]. CRISPRs/Cas9 was also 
tried to inhibit breast cancer. Cyclin-dependent kinases (CDKs) are established 
anti-cancer drug targets, and a new generation of CDK inhibitors provides clinical 
benefits to the patients. Breast cancer cells were genetically manipulated using a 
deactivated CRISPRs/Cas9 (dCRISPR) approach to strengthen the endogenous 
CDK18 promoter to express highly to exhibit an increased sensitivity [41].
3. Conclusion
The gene editing technologies, especially CRISPRs/Cas9, have been extensively 
used as tools in basic research for genome encoding, silencing, enhancing, and 
modification. Currently, they are further applied in manufacturing nonhuman 
therapeutic products and medicinal products. Particularly, the discovery of 
medicinal products using gene editing technologies will open a new era for human 
therapeutics and expect to bring a hope for patient recovery from being seriously 
sick. Many biotechnology companies and pharmaceutical plants have successfully 
produced products using gene editing technologies. For example, CRISPR has 
become an industry which is prosperously developing recently. Nonhuman thera-
peutic products are usually manufactured nonexclusively, while human therapeutic 
products are manufactured exclusively because they are highly technical, ethically 
concerned, and more profitable. Gene editing technologies are very promising in 
applications, though there are still many technical (e.g., off target effects, option of 
delivery tools, localization of function) and ethical challenges (e.g., evaluation of 
benefits and risks, compatibility of private interests and the public good, random 
manipulation of genes, commercialization of human therapy) unsolved. More 
and more products based on these technologies are approved for marketing. We 
also expect the challenges of safety concerns (e.g., genetically modified organism, 
tumorigenesis, etc.) and ethical issues will be overcome in the near future.
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